AIRLINK 69.92 Increased By ▲ 4.72 (7.24%)
BOP 5.46 Decreased By ▼ -0.11 (-1.97%)
CNERGY 4.50 Decreased By ▼ -0.06 (-1.32%)
DFML 25.71 Increased By ▲ 1.19 (4.85%)
DGKC 69.85 Decreased By ▼ -0.11 (-0.16%)
FCCL 20.02 Decreased By ▼ -0.28 (-1.38%)
FFBL 30.69 Increased By ▲ 1.58 (5.43%)
FFL 9.75 Decreased By ▼ -0.08 (-0.81%)
GGL 10.12 Increased By ▲ 0.11 (1.1%)
HBL 114.90 Increased By ▲ 0.65 (0.57%)
HUBC 132.10 Increased By ▲ 3.00 (2.32%)
HUMNL 6.73 Increased By ▲ 0.02 (0.3%)
KEL 4.44 No Change ▼ 0.00 (0%)
KOSM 4.93 Increased By ▲ 0.04 (0.82%)
MLCF 36.45 Decreased By ▼ -0.55 (-1.49%)
OGDC 133.90 Increased By ▲ 1.60 (1.21%)
PAEL 22.50 Decreased By ▼ -0.04 (-0.18%)
PIAA 25.39 Decreased By ▼ -0.50 (-1.93%)
PIBTL 6.61 Increased By ▲ 0.01 (0.15%)
PPL 113.20 Increased By ▲ 0.35 (0.31%)
PRL 30.12 Increased By ▲ 0.71 (2.41%)
PTC 14.70 Decreased By ▼ -0.54 (-3.54%)
SEARL 57.55 Increased By ▲ 0.52 (0.91%)
SNGP 66.60 Increased By ▲ 0.15 (0.23%)
SSGC 10.99 Increased By ▲ 0.01 (0.09%)
TELE 8.77 Decreased By ▼ -0.03 (-0.34%)
TPLP 11.51 Decreased By ▼ -0.19 (-1.62%)
TRG 68.61 Decreased By ▼ -0.01 (-0.01%)
UNITY 23.47 Increased By ▲ 0.07 (0.3%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
BR100 7,394 Increased By 99.2 (1.36%)
BR30 24,121 Increased By 266.7 (1.12%)
KSE100 70,910 Increased By 619.8 (0.88%)
KSE30 23,377 Increased By 205.6 (0.89%)

WASHINGTON: The administration of US President Joe Biden announced plans on Thursday to spend $3.2 billion to accelerate the development and discovery of antiviral treatments against Covid-19 and future threats.

The plan is called the Antiviral Program for Pandemics and its funding comes from the American Rescue Plan, a $1.9 trillion package passed by Congress in March.

"Antivirals are an important complement to existing vaccines, especially for individuals with certain conditions that might put them at a greater risk, for those whom vaccines may not be as protective," Anthony Fauci, the president's chief medical advisor on the pandemic, told reporters.

Antiviral medication can also act as an important line of defense against emerging variants of concern that evade the protective action of current generation vaccines, he added.

The plan will help accelerate clinical testing for oral antiviral pills currently under various stages of development, such as Merck's molnupiravir as well as efforts by Pfizer and Atea-Roche.

The plan is for these to be taken very early after an infection is confirmed, in order to stop the disease from progressing to the severe stage - mimicking what Tamiflu does for influenza. The other pillar of the program is seeding the discovery of new antivirals - not just against this coronavirus and its wider family, but other families of viruses that are believed to have pandemic potential.

Comments

Comments are closed.